SCHEMBL224456

SCHEMBL224456

CC(C)(C)c1[c]c(C(C)(C)C)cc(O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.48
GABRB2 P47870 1/20 0.48
ALDH1A1 P00352 5/20 0.38
ALOX15 P16050 5/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP1A2 P05177 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ATP2A2 P16615 1/20 0.38
ATP2A3 Q93084 1/20 0.38
HSD17B10 Q99714 3/20 0.37
HPGD P15428 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
BACE1 P56817 1/20 0.37
TYR P14679 3/20 0.36
LMNA P02545 2/20 0.36
CYP2C9 P11712 2/20 0.36
NR1I2 O75469 1/20 0.36
MIF P14174 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9006900 0.85 GABRA1 (0.41) GABRA1GABRB2ALDH1A1ALOX15MAPT
SCHEMBL60651 0.74 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2TYRCYP2C9CA2
SCHEMBL150439 0.74 GABRA1 (0.43) GABRA1GABRB2ALDH1A1ALOX15MAPT
SCHEMBL11707700 0.72 TSHR (0.37) ALDH1A1TSHR
SCHEMBL7722741 0.72
SCHEMBL2821369 0.72 ACHE (0.39) ALDH1A1ALOX15MAPTCYP1A2KDM4E
SCHEMBL2395901 0.70 ALDH1A1 (0.40) GABRA1GABRB2ALDH1A1ALOX15MAPT
SCHEMBL27854953 0.70 ALDH1A1 (0.43) GABRA1GABRB2ALDH1A1ALOX15MAPT
SCHEMBL5414773 0.70
SCHEMBL8391443 0.70 HPN (0.33) ALOX15MAPTHPNSIRT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170298058-A1 HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE SHIONOGI & CO (JP) 2017-10-19 US claimed
EP-2604260-B1 NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SHIONOGI & CO (JP) 2017-05-10 EP claimed
US-20160024072-A1 Heterocyclic Ring and Carbocyclic Derivative SHIONOGI & CO., LTD. (JP) 2016-01-28 US claimed
US-20130225596-A1 NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) SHIONOGI & CO., LTD. (JP) 2013-08-29 US claimed
EP-2604260-A1 NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Shionogi&Co., Ltd. (JP) 2013-06-19 EP claimed
US-7402589-B2 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-07-22 US claimed
US-7323511-B2 Post-coupling synthetic approach for polymeric antioxidants UNIVERSITY OF MASSACHUSETTS LOWELL (US) 2008-01-29 US claimed
US-20070299072-A1 KV1.5 POTASSIUM CHANNEL INHIBITORS WYETH (US) 2007-12-27 US claimed
EP-1846460-A2 POST-COUPLING SYNTHETIC APPROACH FOR POLYMERIC ANTIOXIDANTS UNIVERSITY OF MASSACHUSETTS LOWELL (US) 2007-10-24 EP claimed
EP-1737830-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS The Procter and Gamble Company (US) 2007-01-03 EP claimed
WO-2005105757-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-11-10 WO claimed
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-11-03 US claimed
US-20050238789-A1 Post-coupling synthetic approach for polymeric antioxidants UNIVERSITY OF MASSACHUSETTS LOWELL (US) 2005-10-27 US claimed
WO-2005070974-A2 POST-COUPLING SYNTHETIC APPROACH FOR POLYMERIC ANTIOXIDANTS UNIVERSITY OF MASSACHUSETTS LOWELL (US) 2005-08-04 WO claimed
US-5332529-A Dielectric fluids and electrodes TEXACO INC. (US) 1994-07-26 US claimed
US-20170298058-A1 HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE SHIONOGI & CO (JP) 2017-10-19 US disclosed
EP-2604260-B1 NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SHIONOGI & CO (JP) 2017-05-10 EP disclosed
US-5089656-A Forming a phenoxide intermediate, adding an aprotic solvent and an acrylate HIMONT INCORPORATED (US) 1992-02-18 US disclosed
EP-0467063-A2 Process for the preparation of aryl-substituted propionic acid esters Himont Incorporated (US) 1992-01-22 EP disclosed
EP-0272588-A1 Acetylene diurea derivatives and their use in stabilizing synthetic resins BASF Aktiengesellschaft (DE) 1988-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298058-A1 HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE P2RX3, P2RX7, P2RX2 GABRA1 245/4885GABRB2 192/4885ALDH1A1 2515/4885
US-20050245555-A1 Tri-substituted ureas as cytokine inhibitors IL1B, IL1A, IL6 GABRA1 3746/4885GABRB2 3533/4885ALDH1A1 455/4885
US-20160024072-A1 Heterocyclic Ring and Carbocyclic Derivative P2RX3, P2RX7, P2RX2 GABRA1 245/4885GABRB2 192/4885ALDH1A1 2515/4885
US-20130225596-A1 NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) P2RX3, P2RX6, P2RX2 GABRA1 379/4885GABRB2 320/4885ALDH1A1 2598/4885
US-20070299072-A1 KV1.5 POTASSIUM CHANNEL INHIBITORS KCNA5, KCNH1, KCNK5 GABRA1 571/4885GABRB2 806/4885ALDH1A1 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.